So you're sitting on the sidelines waiting for a sign that the markets are safe for reasonable speculation. What are you looking for? Do you want to see a bull market return before committing capital? Are you waiting for signs that the economy is turning the corner? How about corporate earnings improvement?

In the near term I expect to see more and more of the proverbial corporate buybacks. As such, I suggest investors use that event as a signal on individual equity securities. The power of these validations of value can be stunning.

After the market closed on Wednesday, basic materials company, Walter Industries (NYSE: WLT), announced that it would be expanding its stock buyback program by $50 million. On the surface, such amount is a small fraction of the more than $1 billion of market value outstanding, but the move is more than symbolic.

Essentially, management is taking advantage of ridiculously low levels in its stock price. For those looking to establish a position, such a move is a great endorsement of the company and its future.

There were a few stocks in 2008 that exhibited great performance despite horrible market conditions. And these gems of 2008 may provide investors with a safe haven of sorts for 2009.

In fact, we are already hearing analysis of the year to come suggesting that biotechnology stocks will be the place to be for positive returns in the new year.

One such name to consider is Amgen (NASDAQ: AMGN).

Founded in 1980, AMGN is one of the largest biotechnology companies in the market. It has a stable of proven drugs that provides significant profits, and a pipeline of opportunities that should provide reasonable growth in the future.

Shares of AMGN have gained approximately 20% during the last year as investors recognized the value of current profits combined with future growth. Interestingly, the company really gained traction during the second half of the year as the rest of the market was imploding.

Even with the gains, AMGN is a compelling investment story.

Shares trade for 15 times trailing earnings and only 12 times forward earnings. That means you can buy shares for a price-to-earnings ratio that is lower than its growth rate.

One reason for the optimism in the stock in 2008 was the progress made on its osteoporosis drug, Denosumab. Analysts are expecting the drug to be a blockbuster.

Denosumab has done well in trials, and AMGN recently applied for FDA approval to bring the drug to market. Given the expected 10-month FDA review and processing period, AMGN is only a year or so away from the sales benefits of this new drug.